GE MEDICAL SYSTEMS

The FDA has expanded 510(k) clearance for the Xenoview 3T MRI Chest Coil, enabling its use on GE HealthCare's 3T MRI platforms for lung ventilation assessment in adults and pediatric patients aged 12 and older. This follows previous clearances for Philips and Siemens Healthineers systems, broadening access to hyperpolarized MRI technology for high-risk lung disease patients.

Polarean Imaging PLC receives 510k clearance from the US FDA for its MRI chest coil to include GE Healthcare's 3T MRI scanners for Xenon-129 nuclei visualization, now supporting all three major scanner vendors.

The global Nucleic Acid Isolation and Purification market is projected to grow from $7.6B in 2023 to $12B by 2030, driven by molecular diagnostics, genomics research, and personalized medicine. Technological advancements like automated systems and magnetic bead-based purification are key factors shaping the market.

The biochips market, valued at USD 10.35 billion in 2023, is projected to reach USD 35.00 billion by 2032, growing at a CAGR of 14.52%. Driven by personalized medicine, genetic testing, and advanced diagnostics, biochips like DNA chips, microarrays, and lab-on-a-chip devices are crucial in drug development and disease detection. Key players include Thermo Fisher Scientific, Standard BioTools, Randox Laboratories, QIAGEN, PerkinElmer, LI-COR, Illumina, GE HealthCare, Bio-Rad Laboratories, Agilent Technologies, IBIOCHIPS, Cellix Ltd, Nspire Medical Systems, LivaNova PLC, Medtronic, Koninklijke Philips N.V., Nihon Kohden Corporation, Nyxoah SA, and ResMed.

The Image-guided Therapy Market, 2024-2029 report by ResearchAndMarkets.com highlights the rapid growth of the IGT market driven by minimally invasive procedures, technological advancements, and precision medicine. The market is segmented into capital equipment, medical devices, solutions, and clinical applications like oncology, cardiology, neurosurgery, urology, and orthopedics. Key companies include Elekta, Boston Scientific Corporation, Koninklijke Philips N.V., GE HealthCare, and Ziehm Imaging.

The global cancer profiling market is projected to grow from $31.816 billion in 2024 to $59.049 billion by 2029, driven by rising cancer prevalence, biomarker use in tumor profiling, and demand for personalized medicine. Key developments include Guardant Health's tissue genomic profiling test and QIAGEN's NGS analysis tool for stomach cancer. North America leads in market share due to increased cancer research and precision treatment efforts.

The Medical Physics Market is projected to grow from USD 5.16 Bn in 2023 to USD 8.11 Bn by 2031 at a 5.9% CAGR. Medical physics applies physics to healthcare, focusing on imaging, radiation therapy, and nuclear medicine. Key drivers include technological advancements, regulatory support, and the rise of personalized therapy. Major players include GE Healthcare, Siemens, and Varian Medical Systems. Market segments include diagnostics, therapeutics, and end users like hospitals and diagnostic centers. North America leads in market share due to advanced healthcare infrastructure and innovation.

BioIntelliSense received FDA approval for its BioButton Multi-Patient wearable and BioDashboard system, enhancing virtual care and extending patient monitoring into homes. This marks a significant advancement in remote patient monitoring (RPM), which became crucial during the Covid-19 pandemic. GlobalData forecasts the RPM market to grow from $548.9m in 2020 to $760m by 2030, with major players including Boston Scientific, GE Healthcare, and Medtronic. BioIntelliSense's solution automates vital sign collection and delivers real-time data, prioritising patient safety and enhancing clinical outcomes.

GE HealthCare's SIGNA™ MAGNUS, a 3.0T MRI scanner, received FDA 510(k) clearance for neuroimaging, offering enhanced gradient performance and imaging precision, aiding in neurological, oncological, and psychiatric condition detection. The system's innovations include an asymmetrical gradient coil design and HyperG technology, enabling faster, clearer scans and advanced research capabilities.

The FDA has cleared GE HealthCare's Signa Magnus 3T MRI system for head-only scanning, featuring HyperG gradient technology with 300 mT/m and 750 T/m/s performance, enabling faster scans, advanced diffusion imaging, and high SNR. The system's asymmetrical design enhances gradient amplitude and slew rate compared to whole-body MRI platforms.